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Background: Androgen deprivation therapy is commonly used to treat prostate cancer, the most common visceral
cancer in men. However, various side effects often worsen physical functioning and reduce well-being among
men on this treatment. Based on existing evidence, both resistance and aerobic training provide benefits for
this population yet adherence rates are often low. The method of exercise delivery (supervised in-center or
home-based) may be important, yet few studies have compared different models. Additionally, long-term exercise
adherence is critical to achieve sustained benefits but long-term adherence data and predictors of adherence are
lacking. The primary aim of this phase II, non-inferiority randomized controlled trial is to determine whether three
exercise training delivery models are equivalent in terms of benefits in quality of life and physical fitness in this
population. Secondary aims include examination of long-term adherence and cost-effectiveness.
Design: Men diagnosed with prostate cancer, starting or continuing on androgen deprivation therapy for at least
6 months, fluent in English, and living close to one of two experienced Canadian study centers are eligible.
Participants complete five assessments over one year, including a fitness assessment and self-report questionnaires.
Socio-demographic and clinical data collection occur at baseline, bone mineral density testing at two time points,
and blood work is performed at three time points. Participants are randomized in a 1:1:1 fashion to supervised
personal training, supervised group training, or home-based smartphone- and health coach-supported training.
Each participant receives a detailed exercise manual, including illustrations of exercises and safety precautions.
Participants are asked to complete 4 to 5 exercise sessions per week, incorporating aerobic, resistance and flexibility
training. Participant intensity levels will be monitored. The intervention duration is 6 months, with 6 months
additional follow-up. Outcomes include: body composition, fitness testing, quality of life and fatigue, biological
outcomes, and program adherence. Cost information will be obtained using patient diary-based self-report.
Discussion: The goals of this study are to gain a better understanding of health benefits and costs associated with
commonly used yet currently not compared exercise delivery models as well as an increased understanding of
adherence to exercise.
Trial registration: The trial has been registered at clinicaltrials.gov (Registration # NCT02046837), registered January
20th, 2014.
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Prostate Cancer (PC) is the leading cancer diagnosed in
North American men [1,2]. With improvements in early
diagnosis and treatment, survival has been steadily in-
creasing for this population [2]. One common treatment
for men diagnosed with PC is androgen deprivation ther-
apy (ADT), which is estimated to be used in 45% of men
with PC [3,4]. Common side effects from ADT are fatigue,
decreased muscle strength and cardiorespiratory function,
loss of sexual functioning, mood changes, changes in body
composition and negative effects on health-related quality
of life (QOL) [5-8]. These changes often lead to a decrease
in overall physical functioning and individual well-being
[6,9]. Modifiable factors that can limit the burden of ADT
need to be identified.
Exercise in the form of both resistance and aerobic
training provide benefits for individuals with PC on ADT.
In a randomized controlled trial (RCT), Segal et al. [10]
found improvements in fatigue in the exercise group com-
pared to a worsening of fatigue in the control group. Im-
provements in QOL were also noted following this in-
center, structured exercise program [10]. Galvao et al. [11]
found improvements in muscle strength following a 20-
week resistance and endurance training program [11].
Improvements in 6-minute walk tests, stair climbing and
chair rise fitness measures were also observed. In another
study, Galvao et al. found significant improvements in the
general health and physical health composite scores on
the Medical Outcomes Study 36-item questionnaire (SF-
36) for participants who completed a 12-week aerobic and
resistance exercise program, compared to usual care [12].
These trials and others have been included in multiple
systematic reviews of exercise interventions for individ-
uals on ADT for PC. These reviews have found that,
generally, exercise is safe and feasible, and exercise inter-
ventions are associated with multiple benefits for this
population [9,13-16]. For example, Baumann et al. con-
cluded that exercise interventions led to improvements in
fatigue levels, muscular strength, flexibility, aerobic fitness,
QOL, and well-being [9]. Santa Mina et al.’s review also
found similar results regarding physical functioning and
QOL outcomes with the additional finding that exercise
program supervision by a certified professional was an im-
portant factor in achieving greater health benefits [14].
Altogether, findings from these reviews provide strong evi-
dence of exercise benefits for patients on ADT.
Of interest, Thorsen et al. noted that in two of the
studies reviewed, older age was associated with lower
levels of participation intention [13]. This may be particu-
larly important since PC is predominantly an older per-
son’s disease, and aging itself is associated with multiple
functional declines and sarcopenia [17].
While the most consistent benefits of exercise interven-
tions in men on ADT have been seen with 1:1 supervisedprograms [15], few studies have directly compared exer-
cise delivery methods. The systematic review by Keogh
et al. noted significantly greater improvements in out-
comes (physical functioning and QOL) for individuals in
group-based supervised training vs. home-based training
[15]. However, three important things should be noted.
First, the noted improvement with group-based training
compared to home-based training was based on indirect
study comparisons. Second, home-based training provided
significant pre-post increases in aerobic endurance and
reduced fatigue. Third, only one RCT has directly com-
pared multiple exercise delivery methods, comparing
only 1:1 and group supervised training, but with a small
sample size and without a home-based arm [18]. Because
in-center, supervised, exercise programs are resource-
intensive (and largely inaccessible), the demonstration of
similar efficacy in home-based programs to these super-
vised programs would have important health service deliv-
ery implications and economic benefits and may help
expand exercise delivery options for men on ADT.
It is also clear that the benefits obtained from an exer-
cise program are maintained only as long as the exercise
is maintained; therefore ensuring long term adherence
to exercise programming has significant health implica-
tions. In RCTs of exercise in PC, adherence responses to
exercise interventions are moderate to high but vary by
protocol design. Supervised exercise intervention adher-
ence ranged from 79% to 95% (as assessed by attendance
at scheduled sessions) in three studies [10,19,20], whereas
in a study of group-based training the attendance-based
adherence was 94% [11,12]. In three home-based studies,
the adherence ranged from 77% to 100% (assessed by way
of patient reporting, booster session attendance or weekly
group session attendance) [21-23]. In spite of a moderate
to high level of adherence for exercise intervention across
multiple delivery approaches, only Culos-Reed et al. [21]
directly measured changes in activity levels (decreased in
strenuous physical activity, however mild and moderate
physical activity stayed relatively the same) from post-
intervention to subsequent follow-up assessment. Add-
itionally, follow-up assessments of fitness outcomes
following the post intervention assessment [20-23] are
rarely reported. However, when reported longer-term
benefits vary, such that there is evidence of mainten-
ance of intervention-based improvements at 6 months
follow up in one study [20] whereas no differences in
fatigue levels were found from baseline to the end of a
4-week intervention and again 4 weeks later, between
the control and exercise groups [23].Follow-up data
post-intervention were not obtained or reported in four
of the above studies [10,12,19,22].
Even though multiple rigorous studies have demon-
strated improvements in several health outcomes with
an exercise intervention, exercise in the oncology setting
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programs (public and private) and organizations. This
contrasts sharply with cardiovascular rehabilitation, which
is publicly funded in many jurisdictions, in part due to
more advanced, robust evidence demonstrating cost-
effectiveness. Indeed, in today’s fiscally strained funding
environment, there is an increasing emphasis on dem-
onstrating value (or return) on investment. Demonstra-
tion of the cost-effectiveness of exercise programs for
men on ADT could lead to larger scale implementation
of these programs.
Thus, the primary aims of this phase II non-inferiority
RCT are:
 To determine the feasibility of conducting a large
multi-center non-inferiority RCT of three exercise
delivery models in men with PC on ADT. Feasibility
outcomes include participant recruitment, retention,
adherence, outcome capture, and satisfaction;
 To obtain preliminary efficacy estimates for (a)
group-supervised in-centre, and (b) home-based
(smartphone-assisted) supported exercise programs,
compared to (c) a 1:1 supervised in-center exercise
program study for the clinical outcomes of QOL
and physical fitness, and to select a primary outcome
for a subsequent phase III trial;
 To examine adherence to exercise and predictors
of adherence in each exercise group during the
6-month intervention and for 6 months after
program completion;
 To determine the feasibility of conducting an
economic analysis comparing exercise interventions
and usual care.
Methods
This trial is taking place at two experienced academic
tertiary care Canadian centers – the Princess Margaret
Cancer Centre (Toronto, Ontario), and the Tom Baker
Cancer Centre, (Calgary, Alberta). Ethics approval has
been obtained at both institutions. All study participants
provide written informed consent prior to study enrol-
ment. The trial has been registered at clinicaltrials.gov
(Registration # NCT02046837).
Study population/participants
Men diagnosed with histologically confirmed PC of any
stage, starting or continuing on ADT for at least 6 months
(or who remain biochemically castrate after stopping
ADT), able to speak, read and write in English, and living
in close proximity to either study center are eligible for
the study. Each potential participant is screened with the
Physical Activity Readiness questionnaire (PAR-Q+ or
PARmed-X) [24] and/or receives physician approval. If an
individual already meets the American College of SportsMedicine (ACSM) guidelines for moderate to vigorous
physical activity (MVPA) or has a condition that would
interfere with his ability to participate (e.g. severe arthritis
limiting ambulation, major neuropsychiatric abnormality,
severe visual/hearing loss, poorly controlled pain), he is
excluded from the study.Recruitment
The research coordinator at each study site will oversee
recruitment. Estimated time for the recruitment phase
will be 9 months, with the aim of recruiting 100 partici-
pants total. Potential participants are screened through
PC clinics (primarily urology or radiation oncology) at each
site and approached based on initial medical record review
by the research coordinator. Potential participants are pro-
vided with a brief description of the study, and given an
opportunity to ask any questions. If they are interested in
study participation, written informed consent is obtained
and a baseline assessment will be scheduled.Assessments
Participants complete five assessments in total: at base-
line, three months, six months (end of intervention),
nine months, and twelve months. The nine- and twelve-
month assessments provide follow-up information after
completion of the active intervention. Blinded outcome
assessments are conducted by a Certified Exercise Physi-
ologist (CEP; Canadian Society of Exercise Physiology,
CSEP) or Registered Kinesiologist.Baseline assessment
The baseline assessment consists of obtaining socio-
demographic and clinical data as well as assessing
fitness using measures of resting heart rate (HR), blood
pressure (BP), oxygen saturation, body composition (body
mass index, waist circumference and body fat percentage),
upper-lower body strength testing, and cardiovascular
testing (peak VO2). Participants also complete question-
naires (see below) and are scheduled for a bone mineral
density (BMD) test (if one has not been completed in
the last year) and blood work (fasting glucose, prostate-
specific antigen (PSA), testosterone, hemoglobin, and
cholesterol profile). Serum is also banked for ancillary
studies on participants at the Toronto site. All measures
are detailed below and summarized in Table 1.Assessments (three, six, nine and twelve months)
All follow-up assessments include updates on clinical data,
fitness measurements, and self-report questionnaires. BMD
testing occurs only at baseline and twelve months, blood
work and body composition testing is done only at baseline,
six months and twelve-months (Table 1).
Table 1 Summary of study measures at specified time points







FACT-G (primary) 8-10 min ● ● ● ● ●
FACT-P 4-5 min ● ● ● ● ●
FACT-F 5 min ● ● ● ● ●
Physical Fitness
VO2Peak 20 min ● ● ● ● ●
Sit-to-Stand test 1 min ● ● ● ● ●
Grip Strength 1 min ● ● ● ● ●







Bone mineral density 30 min* ● ●
Body composition$ 5 min ● ● ●
Adherence
Accelerometer - ● ● ● ● ●
GLTEQ <5 min ● ● ●
Sessional attendance# -
Adherence Predictor Variables
NEWS-A 10 min ● ● ● ● ●
HCCQ 5 min ● ● ● ● ●
BREQ2 5 min ● ● ● ● ●
ROPAS 5 min ● ● ● ● ●
PAB questionnaire 5 min ● ● ● ● ●
Sedentary Behaviours 5 min ● ● ● ● ●
Cost-Effectiveness
Health questionnaire 5 min ● ● ● ● ●
EQ-5D 5 min ● ● ● ● ●
Study Completion 5 min ●
*Can be done on separate day to reduce participant burden.
$Includes waist circumference, waist circumference:height ratio, and % body fat using bioelectrical impedance analysis.
#Only for those in supervised groups (done weekly).
Abbreviations: BREQ2 Behavioral Regulations in Exercise Questionnaire – 2, EQ-5D EuroQol 5 dimensions of health scale, FACT-G Functional Assessment of Cancer
Therapy General, FACT-F Fatigue subscale, FACT-P Prostate subscale, GLTEQ Godin Leisure Time Exercise Questionnaire, HCCQ Health Care Climate Questionnaire,
Int Intervention, NEWS-A Neighborhood Environment Walkability Scale short form, PAB Planning, Attitudes, & Behavior questionnaire, PSA prostate-specific antigen,
ROPAS Relatedness to Others in Physical Activity scale, VO2 Peak Peak Volume of Oxygen Consumption.
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Participants are allocated to treatment groups following
the baseline assessment through a computer-generated
stratified randomization scheme developed by the study
biostatistician (GT) and administered through an inde-
pendent website. Although the CEP outcome assessorsare blinded to treatment assignment, for practical rea-
sons participants and the intervention CEPs cannot be
blinded. Participants are randomized equally to one of
three groups: 1:1 supervised training, supervised group
training, and home-based smartphone-assisted training.
Randomization is stratified by duration of prior ADT
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suggests that muscle changes and impact on QOL is
most appreciated within the first 3–6 months of ADT
use [6] and exercise response may be partially modified
by duration of ADT [25].
Following randomization, participants are scheduled
to attend their first session (1:1 or group-based training)
or an orientation session (delivered by the study coord-
inator) for home-based training. All participants will re-
ceive a study manual at this time point.
Objective measures/ Primary and secondary outcomes
Body composition
Body composition is measured following the CSEP’s [26]
Canadian Physical Activity Training for Health [27] asses-
sing waist circumference (WC), weight, waist to hip ratio
(WHR), body mass index (BMI). Body fat percentage
(BF%) is measured via bioelectrical impedance analysis
(BIA) using the Tanita TBF-300A device (Illinois, USA).
Additionally, participants receive a BMD scan of the
lumbar spine, total hip, and femoral neck using dual
x-ray absorptiometry.
Fitness testing
Prior to the start of fitness testing, resting HR, BP, and
oxygen saturation are measured. Aerobic fitness is directly
assessed through the modified Bruce treadmill protocol
(treadmill-based graded exercise test) [28], which assesses
volitional peak oxygen consumption (VO2 peak) using a
metabolic cart (Parvo Medics TrueOne 2400 Metabolic
Measurement System). Lower body strength is mea-
sured with a one minute sit-to-stand test [29,30] and
grip strength is used to assess upper body strength. Grip
strength is measured with a Jamar dynamometer aver-
aging three readings obtained in each hand [31].
QOL and fatigue
Functional Assessment of Cancer Therapy – General
(FACT-G) is used to assess general health-related QOL
[32], whereas the FACT-P (Functional Assessment of Can-
cer Therapy - Prostate) evaluates prostate-specific QOL
[33] and the FACT–F (Functional Assessment of Cancer
Therapy – Fatigue) is used to evaluate cancer-related fa-
tigue [34]. All three questionnaires are validated and have
been widely used in cancer research measures, and in par-
ticular, in RCTs of exercise in men on ADT [14].
Biological outcomes (blood data collection)
At three assessment time points (baseline, 6 months and
12 months), participants’ blood is drawn to analyze fast-
ing blood glucose, lipid profile (total cholesterol, low
density lipoprotein, high density lipoprotein, and triglyc-
erides), testosterone, as well as PSA levels. Blood glucose
and lipids are being monitored as ADT is associatedwith an increased risk of both diabetes and dyslipidemia
[35,36]; conversely, exercise is associated with improve-
ments in both metabolic parameters [37]. PSA levels are
being monitored as a safety measure [38], as in other ex-
ercise trials [10,12,39], and testosterone is measured to
assess adequacy of castration.
Adherence
Program adherence and predictors of adherence are
assessed. Adherence measures include physical fitness out-
comes (as the most proximal, objective outcome of exercise
adherence), accelerometry, as well as attendance at exercise
sessions (for those in supervised programs). For those in
the home-based, smartphone-assisted arms, use of the self-
report software (Connected Wellness Platform, NexJ Sys-
tems, Toronto, Canada) and interview responses (obtained
by health coaches) will provide proxies for attendance and
exercise program engagement. Accelerometers (Actigraph
GT3X, Pensacola, FL) will be worn for seven days at each
assessment time point. Accelerometers will be worn during
waking hours, allowing for capture of total physical activity
during the observation period [40]. Data will be extracted
from the accelerometer in 60-second epochs and will be
screened through; (i) at least 4 days of valid data, including
(ii) at least 10 hours of wear time per day; (iii) non-wear
time will be assessed as periods of time with no movement
(0 counts per minute) for more than one hour at a time.
Two common definitions of adherence are adopted: 1)
at least 150 minutes of MVPA per week, based on the
ACSM guideline for cancer survivors [28] and the revised
CSEP guideline for adults and older adults [41]; and 2) at
least 10,000 steps per day [42] for 6+ days per week. In a
sensitivity analysis, a recently described age-specific cut-
off of 7,500 steps per day for older adults [43] is also
tested. The accelerometer data will be analyzed by exam-
ining the total amount of MVPA and sedentary behavior
during the 7 days. MVPA is defined as activity >1952
counts per minute [42] and sedentary behaviour as <100
counts per minute and time spent inclined.
Predictors of adherence are targeted based on a social
ecological framework (Figure 1) [44]. Multiple potential
determinants of exercise adherence and the inter-
relatedness of these determinants are examined using
brief validated measures at each level: exosystem (Neigh-
borhood Environment Walkability Scale: Short Form
(NEWS) [45]); mesosystem (Health Care Climate Ques-
tionnaire [46] and Related to Others in Physical Activity
Scale [47]); and microsystem (Behavioral Regulations in
Exercise Questionnaire-2 [48,49] and a Planning, Atti-
tudes, & Barriers scale [50,51]).
Intervention
The six-month exercise intervention consists of one of
three exercise delivery arms; supervised 1:1 personal
Figure 1 Social ecological framework for understanding exercise determinants.
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home based (smartphone-assisted) training. In all three
intervention arms, each participant meets with a CEP to
receive instructions regarding the exercise program and
orientation to a detailed exercise manual that includes il-
lustrations of exercises and safety precautions for exer-
cising. All participants are asked to complete 4–5 days
per week of mixed modality exercise incorporating
aerobic, resistance and flexibility training, all training
programs are prescribed based on the FITT principle:
Frequency, Intensity, Time and Type. Each program in-
cludes an education component of 12 topics that will
focus on common concerns facing new exercisers (see
Table 2). This occurs during their sessions or weekly
phone calls throughout the intervention period, admin-
istered by the CEP for the 1:1 supervised and group-
based training, and by health coaches for home-based
participants. Both group and 1:1 supervised training
occur under the supervision of a CEP. Participants’ pro-
grams are individualized based on their baseline fitness
assessment, with the target time and absolute workload
(target heart rate: 60-70% of heart rate reserve) kept the
same across all interventions. Relative intensity is main-
tained throughout the program; therefore, participants
are progressed similarly to ensure this occurs (see Pro-
gression section below).
The 10-point Rating of Perceived Exertion (RPE) scale
is used to monitor exercise intensity levels [52], with
participants instructed to maintain their intensity levelat 3–6 during exercise sessions. RPE levels are related to
target HR, as it corresponds to the linear change in HR
[53]. HR monitors (Polar, NY, USA) are used at 3-week
intervals during the exercise sessions across all interven-
tion arms. This is to ensure participants maintain appropri-
ate heart rate levels during the session, ensuring calibration
with the 3–6 rating on the RPE scale throughout the inter-
vention period. Home-based participants are trained to use
HR monitors which are provided to them. Participants in
the supervised 1:1 and group programs will have staff
present to assist in HR measurement.
Study staff will hold monthly conference calls and staff
will be trained on testing and training procedures, to en-
sure standardization across both sites. Supervised exercise
sessions are documented with standard forms at all sites.
Progression
Participant progression is individualized, and monitored
by a CEP or health coach every three weeks to ensure
that progression is occurring. The participant’s intensity
level during the exercises sessions (both aerobic and
resistance) will be used as an indicator of whether the
participant is ready to progress. CEPs or health coaches
adjust intensity levels to ensure participants maintain
the desired intensity range throughout each exercise ses-
sion. Documentation of this progression is completed
using a standard form across all arms of the intervention
and both study sites. Participants who are working below
their target HR when performing aerobic exercise will
Table 2 Education topics
Education topics Key points
1) Introduction to Exercise • Benefits of Physical Activity
• Program targets 3 areas of PA (aerobic, resistance, and flexibility)
• PA is safe, feasible and has shown to provide benefits
2) Goal Setting • Goal setting will assist with your dedication and motivation to complete the exercises
• SMART Goals - Specific, Measurable, Attainable, Realistic, Timely
• Use the goal worksheet in the manual
• Make long term and short term goals
3) Behavior Change • The plan you set out may not be followed 100%
• Anticipate obstacles that may come as you are changing a behaviour and develop strategies for
dealing with it before it arises
• Monitor your progress, Reward yourself, Visualize your success
4) Planning for Barriers • Biggest perceived obstacles
○ Lack of time, self-discipline, partner and ability
• Plan ahead for periods of inactivity
5) Social Support • You are more likely to be successful if your family, friends and even co-workers are supportive of you
• Social support can occur in many forms – encouragement, completing activities with you, etc.
6) Monitoring Behavior • Mix up your activities to stay motivated
• Try something new, or something you have done previously
• It is very easy to enter an exercise rut
7) Maintaining Motivation • Greatest source of motivation: Fun/enjoyment/stimulation, feeling of accomplishment, pleasure of
learning and benefits (i.e. improved sleeping)
• Pursue something that you enjoy, that is convenient to your schedule
• Take opportunities to be active
8) Personal Control • Believing that you are in control of your own life give you reinforced motivation and further
commitment to make changes
9) Self- Discipline, Reward & Attitude • Self-discipline can result in increased productivity, improved self-esteem and confidence
• Rewards – use workbook in manual
• Attitudes toward change can determine whether you will be successful
10) Adapting your Program • Adapting your program – FITT principle
11) Health and the Media • Be mindful of the ‘Get fit quick’ media marketing – Health eating and regular PA will help maintain a
long-term health lifestyle
12) Lifelong Active Living • Use some of the tips and tricks in the manual to assist with continuing your active life
• Change things up, work towards small goals, work with a friend, etc.
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20 minutes), followed by an increase in exercise intensity
(i.e., increase walking speed or grade). Similarly, partici-
pants who are able to complete ≥12 repetitions and 3
sets of a specific resistance exercise will increase the re-
sistance (i.e., blue band to purple band; next resistance
level) they are performing the exercise at to ensure that
they are continuing to progress effectively throughout
the program.
1:1 supervised training
Participants in the 1:1 supervised training complete
three sessions per week with a CEP for a period of sixmonths, and are encouraged to perform one to two add-
itional weekly independent (home-based) sessions. Each
exercise session consists of cardiovascular training for
15 to 30 minutes, resistance training exercises (working
major muscle groups), and flexibility training (including
5–10 minutes of stretching at the end of each session).
All participants are provided with resistance bands for
home use.
Group supervised training
This protocol differs from the 1:1 training protocol in
only one way: a group of 4–6 individuals are supervised
by a CEP at each session.
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The same protocol and training frequency as the 1:1
and group supervised training program is explained
and recommended to be followed by the home-based
smartphone-assisted participants. Along with the re-
sistance bands provided, participants in the home-
based training group also receive a stability ball, an
exercise mat, a HR monitor (with instructions), and a
smartphone with a 6-month paid phone and data plan.
Participants in the home-based arm complete an orien-
tation session with a CEP prior to the commencement
of the training. Participants are oriented to the same
exercise manual that is provided to the supervised
group participants, and review the resistance and flexi-
bility exercises with a CEP to ensure proper technique.
During the orientation participants also meet with the
health coach to review the smartphone application and
the role of the health coach. Remote health coaches
and smartphone technology are intended to provide
support to participants in the home-based training pro-
gram during the intervention phase, as there is no direct
(i.e. face-to-face) supervision with this group. The health
coach connects with participants on a regular basis
(ideally once each week) to follow up on the week’s exer-
cise sessions and to provide guidance for the participants
and assist with any smartphone application issues. Health
coaches instruct the participant when to use the HR mon-
itors to evaluate intensity every three weeks. A customized
smartphone application is used (Connected Wellness Plat-
form) that allows users to input health information, levels




Tapering allows participants within the supervised train-
ing arms to transition from predominately supervised
training to independent exercise training. This is in place
to encourage participants to continue to exercise inde-
pendently at the same intensity and frequency as achieved
during their supervised exercise programs. Tapering oc-
curs for participants in the 1:1 supervised and group-
based training arms. Starting in month five, supervised
sessions are reduced to two sessions per week. In the final
month (month six), supervised sessions are tapered fur-
ther to one session per week. Participants are encouraged
to replace the supervised sessions with equivalent inde-
pendent exercise sessions.
Health coach support
For the home-based group, a similar concept of tapering
will be introduced to reduce the level of support pro-
vided by health coaches. In the first four months the
health coaches will contact each participant once everyweek and will be available seven days per week, with
turnaround time within an hour. In the final two months
of the intervention, the health coaches will contact each
participant once every two weeks and will be available
five days a week. Text message turnaround time will be
reduced from within the hour to next day.
Safety
The CEP reviews with each participant precautions and
safety while exercising during the participant manual
orientation and participants are reminded to review the
manual prior to commencing independent exercise ses-
sions. All exercise trainers have cardiopulmonary resusci-
tation (CPR) and automated external defibrillator (AED)
training and have received safety training at each site. Any
adverse events are document using the National Cancer
Institute common terminology criteria for adverse events
v4.0 [54].
Cost-effectiveness analysis
This phase II study investigates the feasibility of com-
pleting a phase III trial and a full companion economic
evaluation. In the phase II design there will be no formal
cost-utility analysis, however outcomes relevant to eco-
nomic analyses regarding health status will be collected
at each assessment time point using a generic utility in-
strument (the European QOL 5-dimension measure (EQ-
5D)) [55]. Costs are captured with a patient-reported diary
that has been used in prior studies of men with PC
[56,57]. Costs related to health care utilization (e.g. visits
to a physician or physiotherapist), transportation, purchase
of exercise equipment (including gym membership fees),
and related costs are captured at each of the five time
points where QOL and fitness data are captured.
Sample size calculation/power
Following standard guidelines for a phase II RCT [58-60],
we have targeted 30 patients per arm (90 patients in total)
to provide precise estimates of parameters related to the
primary outcomes as well as important feasibility informa-
tion that will be crucial to inform the phase III study.
Assuming 10% drop-out, we will recruit 100 patients
across both sites.
Statistical analysis
Statistical analysis focuses on feasibility outcomes and
those which will inform decisions about moving forward
to and planning a phase III clinical trial. Feasibility out-
comes include recruitment rates, and proportions of
participants retained and adherent at landmark times
throughout the study, all of which will be estimated with
95% confidence intervals. Additionally tallies are kept on
reasons for not participating. Each participant also com-
pletes an exit interview and satisfaction survey which
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study and cost effectiveness analysis.
Adherence is assessed through the two different binary
definitions given previously, based on steps or hours of
exercise. We estimate proportions adhering to exercise
in each three-month period and use generalized estimat-
ing equation logistic regression models to compare adher-
ence between groups and assess predictors of adherence
over the course of the study. Predictors include sociode-
mographic (e.g. age, education), clinical (disease stage),
baseline fitness, and ecological variables (NEWS, etc.).
Quality of Life (FACT-G and FACT-P), musculoskel-
etal fitness, and aerobic fitness are efficacy outcomes
that are analyzed using linear mixed effects model with
subject-specific random effects and group-by-time inter-
actions. The analysis will not focus on differences between
groups, but, to assist with phase III trial design, estimation
of measures of within and between-person variance.
As previously mentioned, there is no formal cost-
effectiveness analysis, however data obtained (diary and
EQ-5D completion and participant acceptance) is used
to help develop this outcome for the phase III study.
Descriptive estimates of costs by category and per inter-
vention arm as well as per site (Toronto, Calgary) will
be calculated.
Criteria to move forward to phase III RCT
To move forward to the phase III intervention, we have
identified pre-specified criteria which must be met dur-
ing the phase II study. Reasonable recruitment (at least
25% of potentially eligible approached participants), ad-
herence (70%) and retention rates (70%), at least moder-
ate satisfaction of participants, and capture of at least
80% of clinical outcomes collected are the minimum cri-
teria. The intention is that all three of the interventions
will move forward to the phase III study; however, if one
arm proves to be inferior to the other two, based on ad-
herence, retention, satisfaction or QOL and physical fit-
ness results, then only two will move to phase III.
Discussion
Increasing amounts of data from well-designed inter-
vention studies have demonstrated statistically and
clinically significant gains in fitness and QOL outcomes
with exercise-based interventions [16]. The most ro-
bust data support 1:1 supervised programs, but these
are resource-intensive and largely inaccessible to most
patients. Whether group-supervised or home-based pro-
grams, both of which are likely significantly less resource-
intensive and more feasible to implement, are equally
effective as 1:1 supervised programs remains unclear.
Altogether, wider adoption of exercise programs is import-
ant as the status quo of the majority of men treated with
ADT is that they remain physically inactive and at risk ofmultiple potentially avoidable side effects [13,61,62]. In
addition, longer-term adherence, after completion of acute
training programs, is key to ensuring ongoing health
benefits, yet few data have been published examining
longer-term follow-up adherence with any exercise de-
livery model. Moreover, little is known about factors
predicting long term adherence; such information can
be used in enhancing longer-term exercise program-
ming effects. Hence, the goals of this study are a better
understanding of health benefits (QOL, physical fitness,
and other clinically relevant endpoints) provided through
three varying exercise delivery models that include evalu-
ation of the cost-effectiveness of program provision (for
men on ADT for PC), and adherence associated with each
approach (during and after the formal six-month interven-
tion period).
The current study is designed to address important limi-
tations in prior studies and advance the science of exercise
delivery for men on ADT. First, this study is directly com-
paring the three main exercise delivery models to identify
whether less resource-intense approaches are as efficacious
as the reference standard of supervised personal training.
Second, adherence will be carefully studied during and,
more importantly, after the formal six-month intervention
period. Moreover, insights will be gained into enabling
factors and barriers to exercise adherence. Third, we will
formally begin to evaluate the cost effectiveness of each ex-
ercise delivery model; such information should ultimately
inform health policy. Additional innovations include struc-
tured exercise tapering (to facilitate independent exercise),
introduction of a smartphone app and health coach support
to enhance home-based exercising, and other features.
The evidence-based knowledge gained with this re-
search will provide an understanding of the best (clinic-
ally effective, high adherence, cost effective) exercise
program for this population and will help strengthen re-
search in this field. Although the results from the phase
II trial will not be definitive, this step is foundational
and the knowledge that will be generated will be incor-
porated into the design and execution of a multi-center
phase III RCT.
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